Evaluation of the effect of curcumin-piperine in the treatment of rheumatoid arthritis

The effect of curcumin-piperine supplementation on inflammatory factors and clinical signs in patients with rheumatoid arthritis: a double-blind clinical trial study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121216011763N53

Enrollment

Registered

2021-08-10

Start date

2021-12-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis. Rheumatoid arthritis with rheumatoid factor

Interventions

Intervention 1: Intervention group: Take one capsule containing curcumin piperine daily (containing 500 mg curcumin extract and 5 mg piperine) for 12 weeks. They will also receive diet and exercise ad

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Willingness to participate in the study Age: 30-70 years Complete informed consent Rheumatoid arthritis according to the rheumatologist according to the criteria of the American College of Rheumatology 2010 Disease activity score higher than 5.1 and total soft joint count (TJC) and swollen joint count (SJC) higher than 8

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Smoking Heart, lung, kidney, hepatitis, cirrhosis, biliary and immune system disorders, hypertension, uncontrolled diabetes, hypothyroidism, Cushing's syndrome Weight loss and bariatric surgery in the last year. Lack of following a special diet and herbal supplements

Design outcomes

Primary

Measure	Time frame
Total antioxidant capacity (TAC). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric method.;C-reactive protein (CRP). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric analysis method and by autoanalyzer.;ESR. Timepoint: Beginning and end of the study. Method of measurement: Enzymatic method.;Clinical signs. Timepoint: Beginning and end of the study. Method of measurement: Diagnosis by a specialist and validated questionnaires.;Superoxide dismutase (SOD). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric method.;Malondialdehyde (MDA). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric method.;Rheumatoid factor (RF). Timepoint: Beginning and end of the study. Method of measurement: ELISA.	—

Measure

Time frame

Total antioxidant capacity (TAC). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric method.;C-reactive protein (CRP). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric analysis method and by autoanalyzer.;ESR. Timepoint: Beginning and end of the study. Method of measurement: Enzymatic method.;Clinical signs. Timepoint: Beginning and end of the study. Method of measurement: Diagnosis by a specialist and validated questionnaires.;Superoxide dismutase (SOD). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric method.;Malondialdehyde (MDA). Timepoint: Beginning and end of the study. Method of measurement: Colorimetric method.;Rheumatoid factor (RF). Timepoint: Beginning and end of the study. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Bagherniya

Esfahan University of Medical Sciences

bagherniya@nutr.mui.ac.ir+98 31 3668 1378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026